|
Pma/510(k)#: k163018.Device evaluation.The device evaluation could not be completed as the device or photographic evidence of the device was not returned for evaluation.This file was created in response to the pmcf study.Manufacturing records.Prior to distribution, all zilbs-635-10-8 devices are subjected to a visual inspection and functional inspection to ensure device integrity.A review of the manufacturing records for zilbs-635-10-8 of lot number c924001 did not reveal any discrepancies that could have contributed to this complaint issue.Instructions for use and/label.As per the instructions for use, ifu0065 which informs the user about the potential adverse events "associated with ercp include, but are not limited to pancreatitis, cholangitis, cholestasis, aspiration, perforation, hemorrhage, infection, liver abscess, sepsis, allergic reaction to contrast or medication, hypotension, respiratory depression or arrest, cardiac arrhythmia or arrest.¿ additional adverse events that occur in conjunction with biliary stent placement include, but are not limited to: trauma to the biliary tract or duodenum, perforation, obstruction of the pancreatic duct, stent migration, stent occlusion, tumor ingrowth or excessive hyperplastic tissue ingrowth, tumor overgrowth, stent misplacement, pain, fever, nausea, vomiting, inflammation, recurrent obstructive jaundice, bile duct ulceration, death (other than due to normal disease progression).It should be noted that the instructions for use (ifu0065) lists stent occlusion as a potential adverse event that can occur in conjunction with biliary stent placement.There is no evidence to suggest the user did not follow the ifu.Image review an image was not returned for evaluation.Root cause analysis: a definitive root cause could not be determined from the available information.A possible root cause can be attributed to patient pre-existing conditions and/or known adverse effects.From the study it is known that the patient had cholangiocarcinoma (bile duct cancer).As per medical advisor input recurrent biliary obstruction (stent occlusions) along with the with abdominal pain and itching was attributed to cholangiocarcinoma (bile duct cancer).As previously noted, stent occlusion and pain are listed as potential adverse events that can occur in conjunction with biliary stent placement.Summary complaint is confirmed based on customer and/or rep testimony.According to the initial reporter, the treatment applied was endoscopic intervention radiofrequency cleaning.On (b)(6) 2015, the patient died.Clinical input received stated that the device did not cause or contribute to the patient death but would have been due to primary disease progression.Complaints of this nature will continue to be monitored for similar events.
|